BiotechTube

Abemaciclib + Darolutamide + LHRH agonist/antagonist

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostatic Neoplasms

Conditions

Prostatic Neoplasms

Trial Timeline

Jan 12, 2024 → Jan 21, 2026

NCT ID
NCT05999968

About Abemaciclib + Darolutamide + LHRH agonist/antagonist

Abemaciclib + Darolutamide + LHRH agonist/antagonist is a phase 1 stage product being developed by Eli Lilly for Prostatic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT05999968. Target conditions include Prostatic Neoplasms.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05999968Phase 1Completed

Competing Products

20 competing products in Prostatic Neoplasms

See all competitors
ProductCompanyStageHype Score
Tadalafil + PlaceboEli LillyPhase 3
77
Placebo + tadalafilEli LillyPhase 3
77
Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
85
tadalafil + placeboEli LillyPhase 2
52
Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue MedicationDaiichi SankyoPhase 1/2
41
Enzalutamide + Abiraterone acetateAstellas PharmaPre-clinical
23
Placebo tamsulosin hydrochloride OCAS 0.4 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg + tamsulosin hydrochloride OCAS 0.4 mg + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
77
Novel hormonal therapyAstellas PharmaPre-clinical
23
ASP3550Astellas PharmaPhase 2
52
Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
85
Novel hormonal therapyAstellas PharmaPre-clinical
23
tamsulosin 0.4mgAstellas PharmaPre-clinical
23
Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
85
Enzalutamide + NSAA + LHRHA or Surgical CastrationAstellas PharmaPhase 3
77
enzalutamide + bicalutamideAstellas PharmaPhase 2
52
Tamsulosin OCASAstellas PharmaApproved
85
degarelixAstellas PharmaPhase 2
52
Tamsulosin OCAS + PlaceboAstellas PharmaApproved
85
Tadalafil + PlaceboEli LillyPhase 2
52
TadalafilEli LillyApproved
85

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85